148 related articles for article (PubMed ID: 34145608)
1. Analysis of risk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination of methods for their avoidance.
Takahashi H; Asaka J; Tairabune T; Ujiie H; Matsuura Y; Nihei S; Kimura T; Chiba T; Kudo K
J Clin Pharm Ther; 2021 Oct; 46(5):1404-1411. PubMed ID: 34145608
[TBL] [Abstract][Full Text] [Related]
2. Effect of risk factors for acneiform rash induced by anti-epidermal growth factor receptor antibody drugs on survival: a retrospective observational study.
Takahashi H; Yaegashi Y; Saito Y; Nihei S; Tairabune T; Ujiie H; Asaka J; Kudo K
J Pharm Health Care Sci; 2022 Sep; 8(1):22. PubMed ID: 36045384
[TBL] [Abstract][Full Text] [Related]
3. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study.
Takahashi H; Saito Y; Sugawara K; Sato M; Tairabune T; Ujiie H; Asaka J; Kudo K
Cancer Chemother Pharmacol; 2024 Apr; 93(4):319-328. PubMed ID: 38017207
[TBL] [Abstract][Full Text] [Related]
6. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
[TBL] [Abstract][Full Text] [Related]
7. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: a retrospective study.
Shinohara A; Ikeda M; Okuyama H; Kobayashi M; Funazaki H; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Ichida Y; Takahashi K; Okusaka T; Saitoh S
Am J Clin Dermatol; 2015 Jun; 16(3):221-9. PubMed ID: 25687689
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer.
Nakajima TE; Boku N; Doi A; Arai H; Mizukami T; Horie Y; Izawa N; Hirakawa M; Ogura T; Tsuda T; Sunakawa Y
Invest New Drugs; 2020 Apr; 38(2):410-418. PubMed ID: 31020609
[TBL] [Abstract][Full Text] [Related]
11. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis.
Gorji M; Joseph J; Pavlakis N; Smith SD
Asia Pac J Clin Oncol; 2022 Dec; 18(6):526-539. PubMed ID: 35352492
[TBL] [Abstract][Full Text] [Related]
12. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
[TBL] [Abstract][Full Text] [Related]
13. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy.
Lacouture ME; Wainberg ZA; Patel AB; Anadkat MJ; Stemmer SM; Shacham-Shmueli E; Medina E; Zelinger G; Shelach N; Ribas A
Cancer Discov; 2021 Sep; 11(9):2158-2167. PubMed ID: 33910927
[TBL] [Abstract][Full Text] [Related]
14. Pre-emptive skin treatments to prevent skin toxicity caused by anti-EGFR antibody: the real-world evidence in Japan.
Yamazaki N; Oomuku Y; Mishiro I; Soeda J
Future Oncol; 2018 Dec; 14(30):3163-3174. PubMed ID: 30215532
[TBL] [Abstract][Full Text] [Related]
15. Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
Dote S; Itakura S; Kamei K; Hira D; Noda S; Kobayashi Y; Terada T
BMC Cancer; 2018 Oct; 18(1):957. PubMed ID: 30290786
[TBL] [Abstract][Full Text] [Related]
16. EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
Chiang TY; Hsu HC; Jane SW; Chen SC
Support Care Cancer; 2020 Oct; 28(10):4771-4779. PubMed ID: 31974771
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Cancer Med; 2019 Aug; 8(9):4169-4175. PubMed ID: 31199595
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatment.
Saito Y; Uchiyama K; Takekuma Y; Komatsu Y; Sugawara M
Support Care Cancer; 2023 Dec; 32(1):8. PubMed ID: 38055053
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
[TBL] [Abstract][Full Text] [Related]
20. Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer.
Annunziata MC; De Stefano A; Fabbrocini G; Leo S; Marchetti P; Romano MC; Romano I
Clin Drug Investig; 2019 Sep; 39(9):825-834. PubMed ID: 31264159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
